BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 12022344)

  • 1. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE; Bochkova AG; Bunchuk NV
    Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.
    Schipper LG; Fransen J; Barrera P; Van Riel PL
    Rheumatology (Oxford); 2009 Jul; 48(7):828-33. PubMed ID: 19458163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.
    Ribbens C; Andre B; Jaspar JM; Kaye O; Kaiser MJ; De Groote D; Malaise MG
    J Rheumatol; 2000 Apr; 27(4):888-93. PubMed ID: 10782811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?
    Schipper LG; Fransen J; Barrera P; den Broeder AA; Van Riel PL
    Rheumatology (Oxford); 2009 Oct; 48(10):1247-53. PubMed ID: 19638454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
    Lie E; Uhlig T; van der Heijde D; Rødevand E; Kalstad S; Kaufmann C; Mikkelsen K; Kvien TK
    Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
    J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
    Durez P; Nzeusseu Toukap A; Lauwerys BR; Manicourt DH; Verschueren P; Westhovens R; Devogelaer JP; Houssiau FA
    Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
    Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
    Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
    Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
    Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.